{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:00Z","timestamp":1792001460017,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/rheumatology\/key175","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T19:15:53Z","timestamp":1527102953000},"page":"1802-1811","source":"Crossref","is-referenced-by-count":61,"title":["Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review"],"prefix":"10.1093","volume":"57","author":[{"given":"Natalia","family":"Pittman","sequence":"first","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara M","family":"Rawn","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mianbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Canadian Scleroderma Research Group, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Masetto","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sherbrooke University, Sherbrooke, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A","family":"Beattie","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Larch\u00e9","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,2]]},"reference":[{"key":"key\n\t\t\t\t20180924092224_key175-B1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"key":"key\n\t\t\t\t20180924092224_key175-B2","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a Longitudinal EUSTAR Study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180924092224_key175-B3","article-title":"The gastrointestinal dysmotility and infections in systemic sclerosis- a real world scenario","author":"Sharma","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"key\n\t\t\t\t20180924092224_key175-B4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00296-017-3680-y","article-title":"Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis","volume":"37","author":"Zekovic","year":"2017","journal-title":"Rheumatol Int"},{"key":"key\n\t\t\t\t20180924092224_key175-B5","first-page":"242","article-title":"Gastrointestinal symptoms in scleroderma patients and its influence in body mass index and quality of life","volume":"39","author":"Skare","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"key\n\t\t\t\t20180924092224_key175-B6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.3899\/jrheum.110826","article-title":"Effect of gastrointestinal manifestations on quality of life in 87 consecutive patients with systemic sclerosis","volume":"39","author":"Omair","year":"2012","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t20180924092224_key175-B7","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kep226","article-title":"Small intestinal bacterial overgrowth in systemic sclerosis","volume":"48","author":"Marie","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"key\n\t\t\t\t20180924092224_key175-B8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2008.096545","article-title":"Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility","volume":"68","author":"Kawaguchi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180924092224_key175-B9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180924092224_key175-B10","article-title":"Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms","volume":"32(6 Suppl 86)","author":"Tauber","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"key\n\t\t\t\t20180924092224_key175-B11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.24730","article-title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument","volume":"61","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180924092224_key175-B12","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1002\/acr.20598","article-title":"Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials","volume":"63(Suppl 11)","author":"Pope","year":"2011","journal-title":"Arthritis Care Res"},{"key":"key\n\t\t\t\t20180924092224_key175-B13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/ajg.2017.46","article-title":"Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus","volume":"112","author":"Razaie","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180924092224_key175-B14","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20180924092224_key175-B15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.semarthrit.2016.12.003","article-title":"Evidence-based management of systemic sclerosis: navigating recommendations and guidelines","volume":"46","author":"Pellar","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t20180924092224_key175-B16","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/apt.12456","article-title":"Review article: small intestinal bacterial overgrowth\u2013prevalence, clinical features, current and developing diagnostic tests, and treatment","volume":"38","author":"Grace","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180924092224_key175-B17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.13928","article-title":"Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth","volume":"45","author":"Gatta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180924092224_key175-B18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000814","article-title":"Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence","volume":"51","author":"Zhong","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"key\n\t\t\t\t20180924092224_key175-B19","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180924092224_key175-B20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/rheumatology\/34.3.265","article-title":"Small bowel bacterial overgrowth in systemic sclerosis: detection using direct and indirect methods and treatment outcome","volume":"34","author":"Kaye","year":"1995","journal-title":"Br J Rheumatol"},{"key":"key\n\t\t\t\t20180924092224_key175-B21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/j.1572-0241.2007.01758.x","article-title":"Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication","volume":"103","author":"Parodi","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20180924092224_key175-B22","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180924092224_key175-B23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"key\n\t\t\t\t20180924092224_key175-B24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/art.1780230510","article-title":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","volume":"23","year":"1980","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180924092224_key175-B25","first-page":"1747","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20180924092224_key175-B26","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1046\/j.1365-2036.2003.01800.x","article-title":"Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn\u2019s disease","volume":"18","author":"Castiglione","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180924092224_key175-B27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/rheumatology\/34.10.976","article-title":"Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma","volume":"34","author":"Gough","year":"1995","journal-title":"Br J Rheumatol"},{"key":"key\n\t\t\t\t20180924092224_key175-B28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","article-title":"Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth","volume":"53","author":"Su","year":"2018","journal-title":"J Gastoenterol"},{"key":"key\n\t\t\t\t20180924092224_key175-B29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","article-title":"Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth","volume":"38","author":"Shah","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20180924092224_key175-B30","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","article-title":"Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis","volume":"11","author":"Lo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20180924092224_key175-B31","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4270","article-title":"Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide","volume":"15","author":"Villano","year":"2013","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/57\/10\/1802\/25827485\/key175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T11:38:43Z","timestamp":1571398723000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/57\/10\/1802\/5048122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,2]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,7,2]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key175","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10]]},"published":{"date-parts":[[2018,7,2]]}}}